Saturday 17 October 2026
Export ELTX’s income statement to Excel — free account
Elicio Therapeutics, Inc.
ELTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 34.9%, free cash flow grew 8.77% and total debt rose 2.12%, each against the same quarter a year earlier.
1.56
0.22
−12.36%
Follow ELTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
604.57% | 817.92% | (1,076.34%) | (774.56%) | |
| (137.56%) | (146.45%) | (158.11%) | (124.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(300.15%) | (344.22%) | (435.85%) | (229.40%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.33) | (2.42) | (2.11) | (1.96) | |
Free Cash Flow |
(38.90) | (37.05) | (38.48) | (37.69) | |
Capital Expenditures |
— | (0.10) | — | — | |
| Other line items | |||||
Cash ROIC |
(113.92%) | (125.16%) | (167.40%) | (92.04%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(41.16) | (33.29) | (27.55) | (24.00) | |
Operating CF/Net income |
0.85 | 0.93 | 0.96 | 1.00 | |
Depreciation/Fixed assets |
3.75 | 4.56 | 5.58 | 6.81 | |
Capex/Depreciation |
0.00 | (0.08) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.33) | (2.41) | (2.11) | (1.96) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates